Citius pharmaceuticals completes enrollment in the pivotal phase 3 study of its cancer immunotherapy i/ontak for the treatment of cutaneous t-cell lymphoma

Cranford, n.j., dec. 6, 2021 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it has completed patient enrollment in its pivotal phase 3 trial of i/ontak, an engineered il-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous t-cell lymphoma (ctcl).
CTXR Ratings Summary
CTXR Quant Ranking